New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - betamethasone valerate 0.1%{relative}; clioquinol 3%{relative};   - topical cream - 0.1%/3% - active: betamethasone valerate 0.1%{relative} clioquinol 3%{relative}   - betnovate-c preparations are indicated for the treatment of the following conditions where secondary bacterial and/or fungal infection is present, suspected or likely to occur:- eczema including atopic, and discoid eczemas. prurigo nodularis. psoriasis (excluding widespread plaque psoriasis). neurodermatoses including lichen simplex, lichen planus. seborrhoeic dermatitis. contact sensitivity reactions. insect bite reactions. prickly heat. anal and genital intertrigo. otitis externa.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 125ug;   - aerosol inhaler, metered dose - 125 mcg/dose - active: fluticasone propionate 125ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 250ug;   - aerosol inhaler, metered dose - 250 mcg/dose - active: fluticasone propionate 250ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 50ug;   - aerosol inhaler, metered dose - 50 mcg/dose - active: fluticasone propionate 50ug   excipient: norflurane - fluticasone propionate has a marked anti-inflammatory effect in the lungs. it reduces symptoms and exacerbations of asthma in patients previously treated with bronchodilator alone or with other prophylactic therapy. severe asthma requires regular medical assessment as death may occur. patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and pef values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after a bronchodilator. these patients will require high dose inhaled (see dosage instructions) or oral corticosteroid therapy. sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 1 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 2 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2 g excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ceftazidime pentahydrate 500mg - powder for injection - 500 mg - active: ceftazidime pentahydrate 500mg excipient: sodium carbonate - treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - neisseria meningitidis group a polysaccharide 100 µg/ml; neisseria meningitidis group c polysaccharide 100 µg/ml - powder for injection - 50µg,50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 100 µg/ml neisseria meningitidis group c polysaccharide 100 µg/ml excipient: lactose monohydrate

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group a polysaccharide 50ug;  ; neisseria meningitidis group c polysaccharide 50ug;  ; neisseria meningitidis group w135 polysaccharide 50ug;  ; neisseria meningitidis group y polysaccharide 50ug;   - suspension for injection - 50µg/0.5ml - active: neisseria meningitidis group a polysaccharide 50ug   neisseria meningitidis group c polysaccharide 50ug   neisseria meningitidis group w135 polysaccharide 50ug   neisseria meningitidis group y polysaccharide 50ug   excipient: sucrose trometamol sodium chloride water for injection - mencevax acwy is indicated for active immunisation of adults and children over two years against meningococcal meningitis caused by group a, group c, group w-135 and group y meningococci. the vaccine may also be used for: · subjects who are close contacts of patients with disease caused by meningococci of groups a, c, w-135 and y. · travellers to countries where the disease is epidemic or highly endemic. · controlling epidemics of infection caused by group a, c, w-135, y meningococci in confined communities. mencevax acwy is not recommended for use in infants and children under two years of age, as antigenicity of the vaccine is low in this age group and antibodies persist for shorter duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - haemophilus influenzae type b prp 5ug (conjugated with 12.5 mcg tetanus toxoid);  ; neisseria meningitidis group c polysaccharide 5ug (5 mcg men c polysaccharide conjugated to 5 mcg tetanus toxoid) - injection with diluent - 0.5 ml - active: haemophilus influenzae type b prp 5ug (conjugated with 12.5 mcg tetanus toxoid)   neisseria meningitidis group c polysaccharide 5ug (5 mcg men c polysaccharide conjugated to 5 mcg tetanus toxoid) excipient: sodium chloride sucrose tetanus toxoid trometamol hydrochloride sodium chloride water for injection - menitorix is indicated for the prevention of invasive diseases caused by haemophilus influenzae type b (hib) and neisseria meningitidis serogroup c (menc).